股票 
板块 
用户 
资讯 Swipe Left for English News→
意大利米兰，2026年10月6日至8日，为期三天的 CPHI Milan 2026 正式落下帷幕。作为全球制药行业极具影响力的专业盛会，本届展会汇聚来自全球各地制药企业、生物技术公司、CDMO 服务商，聚焦药物开发、供应链保障与产业协作。博腾股份亮相本次行业盛会，于 10K6 展位与来自欧洲及全球的制药企业、Biotech 与行业伙伴开展多场面对面洽谈，共同探讨药物开发趋势、供应链挑战与 CDMO 多元合作机遇。
图注：博腾团队于 CPHI Milan 2026 10K6 展位合影
依托分布在中美多地的研发与 GMP 生产场地，以及欧洲比利时、瑞士等地的销售办公室，博腾执行统一的全球质量与运营管理体系，为客户提供就近对接的技术服务与稳定可靠的全球化供应链交付保障。本届米兰展，博腾重点展示 DS-DP 原料药到制剂一体化 CDMO 服务能力，业务版图覆盖小分子、TIDES 多肽与寡核苷酸、ADC/AOC 等新型偶联药物及先进疗法药物（ATMP）平台，贯穿临床前开发、临床样品制备到商业化生产完整链条，现场与行业伙伴共同探讨复杂分子 CMC 开发、高活性原料药（HPAPI）的合成与 GMP 生产、工艺放大以及全球化项目交付的实践经验。
在博腾，我们深知技术是驱动医药创新的核心力量。公司成立于 2005 年，二十余年来博腾持续加大研发投入，打造覆盖药物研发生产全流程的先进技术平台和一体化管理体系。我们为全球药企、生物科技公司及科研机构提供从临床前研究到药品上市全生命周期的端到端定制研发与生产服务，覆盖小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物从原料药到制剂的完整链条。截至 2026 年 6 月 30 日，公司全球雇员达 4,400 余人，已与全球 1,500 余家客户建立业务合作，累计成功交付约 6,000 个新药开发项目。（www.portonpharma.com）
公司多平台并行发展：
小分子药物 CDMO服务平台，拥有关键中间体、原料药到制剂的完整开发与规模化生产能力；
多肽与寡核苷酸药物 CDMO 服务平台，能为多肽、小核酸药物提供从早研、原料药工艺开发与生产、到处方开发与制剂生产、分析方法开发与验证、全球新药注册申报支持等一站式CMC服务；
蛋白与偶联药物 CDMO服务平台，涵盖 Linker-Payload 开发、偶联工艺、分析表征到制剂生产全链条，支持 ADC、AOC、DAC、PDC、RDC 等各类 XDC 新型偶联药物CMC 开发需求；
ATMP先进疗法 CDMO 平台涵盖质粒、病毒载体、细胞治疗产品、mRNA-LNP、活菌载体及外泌体等 CGT 产品，满足从临床前研究到商业化生产的全流程需求。
依托北美 J-STAR Research 研发生产基地，博腾实现中美两地高效协同，面向欧美创新药企输出聚焦小分子、Linker-Payload 及 HPAPI 的本地化研发与 GMP 制造服务。
本届展会期间，博腾商务、技术与供应链团队共同驻场，接待了大量到访展位的行业来宾。针对欧美 Biotech 和制药企业在复杂分子工艺开发、高活物料生产、跨区域供应链管理、全球多地区 IND 申报等现实痛点，团队与来访客户开展深度沟通，结合大量已落地项目案例，探讨定制化 CMC 解决方案。多轮现场会谈进一步加深了博腾与欧洲行业伙伴的联结，挖掘潜在的长期合作契机。
左右滑动查看更多
感谢所有莅临 10K6 展位的客户、合作伙伴与行业同仁，感谢大家与博腾共同交流创新思路、探索合作机会。期待后续持续开展深度交流。
展望未来，博腾股份将继续秉持“让好药更早惠及大众”的使命，坚持以客户为中心，以更加开放的姿态、更加创新的思维和卓越的 DS-DP 一体化协同服务，与全球医药行业同仁携手共进，推动医药创新，为人类健康事业贡献更多力量。
商务联系邮箱：business@portonpharma.com
2027年11月，CPHI 法兰克福再见！
继 CPHI Milan 之后，博腾 10 月还将亮相北美两场重磅行业大会：
World ADC San Diego（10 月 12?15 日｜美国圣迭戈）
点击“阅读原文”查看会议详情
AAPS PharmSci 360（10 月 25?28 日｜美国新奥尔良）
点击“阅读原文”查看会议详情
欢迎行业伙伴预约现场会谈，开展技术交流与合作洽谈。
博腾股份成立于2005年，为全球药企、生物科技公司及科研机构等提供从临床前研究到药品上市全生命周期的端到端 CDMO 服务，涵盖小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物的原料药到制剂全流程。截至2026年6月30日，公司拥有全球员工4,400余人，累计服务客户1,500余家，成功交付项目约6,000个。我们始终坚持以客户为中心，致力于提供创新可靠的全球化 CDMO 解决方案，让好药更早惠及大众。
Milan, Italy, October 6th to 8th, 2026 — The three-day CPHI Milan 2026 has officially drawn to a close. As one of the most influential professional gatherings in the global pharmaceutical industry, this year’s event brought together pharmaceutical companies, biotech firms, and CDMO service providers from around the world to focus on drug development, supply chain resilience, and industry collaboration. Porton Pharma Solutions showcased its capabilities at the event, engaging in multiple face-to-face meetings with pharmaceutical and biotech companies and industry partners from Europe and around the world at Booth 10K6, discussing drug development trends, supply chain challenges, and diverse CDMO collaboration opportunities.
Porton team group photo at Booth 10K6, CPHI Milan 2026
Leveraging its R&D and GMP manufacturing sites across China and the United States, as well as sales offices in Belgium, Switzerland, and other locations in Europe, Porton operates under a unified global quality and operational management system, providing clients with locally accessible technical services and reliable global supply chain delivery assurance. At CPHI Milan 2026, Porton highlighted its integrated DS-DP CDMO capabilities from drug substance to drug product. Its business covers Small Molecules, Tides, Biologics and Conjugates, as well as Advanced Therapy Medicinal Products (ATMPs), covering the full chain from preclinical development and clinical manufacturing to commercial production. Onsite, the team and industry partners discussed practical experience in complex molecule CMC development, the synthesis and GMP manufacturing of HPAPIs, process scale-up, and global project delivery.
At Porton, we understand that technology is the cornerstone of pharmaceutical innovation. Founded in 2005, Porton has consistently invested in R&D over more than two decades, building an advanced technology platform and an integrated management system covering the entire drug R&D and production process. As of June 30, 2026, Porton has more than 4,400 employees worldwide, built business relationships with more than 1,500 customers globally, and successfully delivered approximately 6,000 new drug development projects. (www.portonpharma.com)
Porton End-to-end CDMO Services Platform
Small Molecules CDMO Service Platform offers comprehensive CMC solutions for small molecule drugs through our advanced technical capabilities. Our services encompass intermediates (INT) and drug substances (DS) process development and manufacturing, formulation development and drug product (DP) manufacturing, comprehensive quality research, and IND/NDA filing support.
TIDES CDMO Service Platform provides comprehensive services for peptide drugs and oligonucleotide drugs, including early-stage research, process development and manufacturing, formulation development and drug product manufacturing, analytical method development and validation, as well as global regulatory affairs support.
Biologics and Conjugates CDMO Service Platform offers comprehensive services for biologics and conjugate products (ADC, AOC, DAC, PDC,RDC and etc.), including early research, process development and manufacturing, formulation development and drug product manufacturing, analytical method development and validation, and global new drug regulatory affairs support.
The ATMPs CDMO Platform covers plasmids, viral vectors, cell therapies, mRNA-LNP, bacterial vectors, and exosomes for CGT products, spanning from preclinical research through clinical stages to commercial manufacturing.
Leveraging its J-STAR Research R&D and manufacturing site in North America, Porton achieves efficient China-U.S. collaboration and delivers localized R&D and GMP manufacturing services.
Throughout the event, Porton’s business, technical, and supply chain teams worked side by side on site, welcoming numerous industry visitors to Booth 10K6. Addressing the practical challenges facing European biotech and pharmaceutical companies, the team held a series of on-site meetings that strengthened Porton’s ties with European industry partners and uncovered promising opportunities for long-term collaboration.
View More
Thank you to all customers, partners, and industry peers who visited Booth 10K6, and thank you for joining Porton in exchanging innovative ideas and exploring collaboration opportunities. We look forward to continuing in-depth exchanges in the future.
Looking ahead, Porton will continue to uphold its mission of “Enabling Earlier Access to Good Medicines,” remain customer-centric, and work with global pharmaceutical industry peers with a more open approach, more innovative thinking, and outstanding integrated DS-DP synergistic services to drive pharmaceutical innovation and contribute more to human health.
Business contact: business@portonpharma.com
See you at CPHI Frankfurt in November 2027!
Following CPHI Milan, Porton will participate in two key industry conferences across North America in October:
World ADC San Diego（October 12th to 15th｜San Diego, USA）
Visit the offline meeting section on Porton's official website (click read more)
AAPS PharmSci 360（October 25th-28th｜New Orleans, USA）
Visit the offline meeting section on Porton's official website (click read more)
Industry partners are welcome to schedule on site meetings for technical exchanges and collaboration discussions.。
Founded in 2005, Porton Pharma Solutions provides end-to-end CDMO services from pre-clinical to commercial stages. Our capabilities span Small Molecules, TIDES, Biologics and Conjugates (ADCs, AOCs, DACs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products, from drug substance to drug product. As of June 30, 2026, Porton had over 4,400 employees globally, served more than 1,500 customers, and delivered approximately 6,000 projects. We are committed to a customer-centric approach, delivering innovative and reliable global CDMO solutions, enabling earlier access to good medicines.
评论 (0)